MorphoSys AG (MOR)
| Previous close | 18.37 |
| Open | 18.14 |
| Bid | 13.12 x 200 |
| Ask | 23.65 x 200 |
| Day's range | 18.14 - 18.47 |
| 52-week range | 4.18 - 19.50 |
| Volume | |
| Avg. volume | 231,337 |
| Market cap | 2.774B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.50 |
| Earnings date | 07 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.47 |
Business WireMorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
PLANEGG/MUNICH, Germany, July 12, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares ("ADSs") from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act").
Business WireMorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
PLANEGG/MUNICH, Germany, June 20, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as "Novartis") also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squ
ZacksBiogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
